References
- White CM. Pharmacologic effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol 1999;39:111–8
- Haffner SM. Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors. Circulation 2001;103:346–7
- Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a prospective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357–62
- Shepard J, Cobbe S, Ford I, et al. Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995;333;1301–7
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005–16
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22
- Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003;26:2713–21
- Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet 2003;361:1149–58
- Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. New Engl J Med 2007;357:10.1056/NEJMoa0706201
- American Diabetes Association. Standards of medical care in diabetes – 2007. Diabetes Care 2007;30(Suppl 1): s4–s41
- Gillespie EL, White CM, Kardas M, et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005;28:2261–6
- White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002;42:1–8
- Mann DM, Allegrante JP, Natarajan S, et al. Dietary indiscretion and statin use. Mayo Clin Proc 2007;82:951–3